Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARCAGY/ GINECO GROUP
With
Roche Pharma AG
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18 years and over,
Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
Patients should be informed of the study orally and should not have any objection their data to be processed.
You may not be if
Patient participation in a clinical trial
Patient non-affiliated to a social security scheme.
Clareo Health | First Line Ovarian Cancer Treatment - Cohort Study
